Background
What is Tuberculosis (TB)?
Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis.
It primarily affects the lungs (pulmonary TB), but can also affect the brain, bones, kidneys and other organs (extrapulmonary TB).
It spreads through the air when a person with infectious pulmonary TB coughs, sneezes or spits.
TB is preventable and curable with appropriate antibiotic treatment.
Common symptoms include persistent cough, fever, night sweats, weight loss, fatigue and loss of appetite.
Types of TB
Drug-susceptible TB: TB bacteria respond to standard first-line medicines.
Drug-resistant TB: TB bacteria become resistant to one or more medicines used for treatment.
Multidrug-resistant TB (MDR-TB): TB bacteria are resistant to at least isoniazid and rifampicin, two important first-line drugs.
Latent TB infection: A person carries TB bacteria but does not have active TB disease and cannot transmit it.
Global Scenario: WHO Report 2026
The South-East Asia Region accounted for 35% of new TB cases globally in 2025.
The Western Pacific Region accounted for 27%, while the African Region contributed 25%.
Around 88% of new TB cases were concentrated in 30 countries.
India accounted for approximately one-fourth of global new TB cases.
Globally, approximately 1.13 million people died due to TB in 2025.
Around 50% of people treated for TB and their households faced catastrophic costs exceeding 20% of household income.
Key Features
Reduction in mortality: India recorded a 38% decline in TB mortality since 2015, compared with a global decline of 35%.
High treatment success: India achieved a 94% treatment success rate among patients with drug-susceptible TB.
High disease burden: India continues to account for approximately 25% of new TB cases worldwide.
Regional concentration: South-East Asia remains the region with the largest share of new TB cases.
Drug-resistant TB: MDR-TB continues to pose a major public health and health security challenge.
Economic burden: TB treatment involves direct medical expenses, non-medical expenditure and indirect income losses, pushing vulnerable households into financial hardship.
Government Initiatives to Eliminate TB in India
National TB Elimination Programme (NTEP)
Formerly known as the Revised National Tuberculosis Control Programme (RNTCP).
Focuses on early diagnosis, quality treatment, prevention and surveillance.
Aims to eliminate TB in India by 2025, ahead of the global Sustainable Development Goal target of 2030. However, this target has not yet been achieved.
TB Mukt Bharat Abhiyaan
Launched in 2024 to accelerate TB elimination through community participation.
Encourages individuals, organisations and institutions to support TB patients.
The campaign has expanded screening and nutritional support.
Between December 7, 2024 and November 8, 2026, more than 25 crore individuals were brought within the scope of screening.
Ni-kshay Poshan Yojana
Provides financial assistance to TB patients for nutritional support during treatment.
Helps reduce the nutritional and economic burden associated with the disease.
Ni-kshay Portal
A digital platform for TB patient registration, tracking, monitoring and treatment management.
Strengthens surveillance and continuity of care.
Pradhan Mantri TB Mukt Bharat Abhiyaan – Ni-kshay Mitra Initiative
Encourages individuals, NGOs, corporates and institutions to adopt and support TB patients.
Provides nutritional, diagnostic and vocational support through community participation.
BPaLM Treatment Regimen
A newer treatment approach for eligible patients with drug-resistant TB.
Combines bedaquiline, pretomanid, linezolid and moxifloxacin.
Helps improve treatment outcomes and reduce treatment duration for eligible patients.
Challenges
High disease burden: India continues to contribute a substantial proportion of global TB cases.
Drug resistance: Increasing concerns regarding MDR-TB and other forms of drug-resistant TB complicate treatment.
Undernutrition: Poor nutritional status increases susceptibility to TB and delays recovery.
Poverty and economic hardship: Treatment-related expenditure and loss of wages push vulnerable households into financial distress.
Social stigma: Discrimination and misconceptions discourage patients from seeking timely diagnosis and completing treatment.
Delayed diagnosis: Limited awareness, inadequate screening and difficulties in accessing diagnostic facilities lead to late detection.
Way Forward
Strengthen early diagnosis: Expand molecular diagnostic facilities, mobile testing units and community-level screening, particularly in high-burden areas.
Address nutritional deficiencies: Ensure timely nutritional assistance and promote food security among vulnerable TB patients.
Combat drug-resistant TB: Improve access to newer treatment regimens, drug-susceptibility testing and patient-centred care.
Improve public-private partnerships: Integrate private healthcare providers into national TB surveillance and treatment systems.
Increase community participation: Involve Panchayati Raj Institutions, NGOs, civil society and local communities in awareness and screening campaigns.
Address social determinants: Improve sanitation, housing, nutrition and living conditions, which influence TB vulnerability.
Conclusion
The 38% decrease in mortality from TB and 94% treatment success rate show that India has taken steps in its battle against the disease. The fact that India accounts for a large proportion of global TB incidence figures and the problem of drug resistance is becoming more significant shows the need to maintain efforts. Elimination of TB demands a holistic effort



